Q-omics provides the consensus-scored PCYOX1L profile across patient tissues and cancer cell-line models. PCYOX1L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PCYOX1L is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PCYOX1L RNA expression shows 19,611 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where PCYOX1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCYOX1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCYOX1L survival associations across molecular data types. PCYOX1L RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCYOX1L RNA expression–survival associations across cancer types. High PCYOX1L expression shows unfavorable associations in KIRC, THCA, MESO and LIHC, but favorable associations in LUSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PCYOX1L RNA expression.
This table summarizes PCYOX1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PCYOX1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCYOX1L shows higher tumor expression in HNSC, COAD, KIRC, BRCA, LIHC and BLCA. The HNSC box plot shows higher PCYOX1L RNA expression in tumor versus normal tissue (log2 FC = +0.614, t-test p < 0.001).
This table shows molecular features associated with PCYOX1L in patient tissues and cancer cell lines. In patient samples, PCYOX1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCYOX1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
